Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Insmed (INSM) EBITDA Margin (2018 - 2026)

Insmed's EBITDA Margin history spans 12 years, with the latest figure at 53.93% for Q1 2026.

  • Quarterly EBITDA Margin rose 22099.0% to 53.93% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 144.33% through Mar 2026, up 12141.0% year-over-year, with the annual reading at 209.92% for FY2025, 4174.0% up from the prior year.
  • EBITDA Margin came in at 53.93% for Q1 2026, up from 124.7% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 53.93% in Q1 2026 to a low of 334.07% in Q2 2024.
  • The 5-year median for EBITDA Margin is 228.25% (2024), against an average of 222.97%.
  • Year-over-year, EBITDA Margin tumbled -17229bps in 2023 and then skyrocketed 22099bps in 2026.
  • Insmed's EBITDA Margin stood at 266.41% in 2022, then rose by 17bps to 220.72% in 2023, then decreased by -3bps to 228.25% in 2024, then soared by 45bps to 124.7% in 2025, then soared by 57bps to 53.93% in 2026.
  • Per Business Quant, the three most recent readings for INSM's EBITDA Margin are 53.93% (Q1 2026), 124.7% (Q4 2025), and 259.77% (Q3 2025).